Home » Stocks » PAVM

PAVmed Inc. (PAVM)

Stock Price: $4.92 USD 0.06 (1.23%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $4.90 -0.02 (-0.41%) Apr 16, 7:54 PM
Market Cap 405.71M
Revenue (ttm) n/a
Net Income (ttm) -34.56M
Shares Out 47.43M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $4.92
Previous Close $4.86
Change ($) 0.06
Change (%) 1.23%
Day's Open 4.87
Day's Range 4.67 - 4.98
Day's Volume 2,543,986
52-Week Range 1.63 - 6.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today ann...

1 week ago - GlobeNewsWire

On-demand corporate presentation scheduled for March 17, 2021

1 month ago - GlobeNewsWire

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announc...

1 month ago - GlobeNewsWire

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today ann...

1 month ago - GlobeNewsWire

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

1 month ago - GlobeNewsWire

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

1 month ago - GlobeNewsWire

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

1 month ago - GlobeNewsWire

Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company

1 month ago - GlobeNewsWire

Conference call and live webcast was previously scheduled for 4:30 PM EST

1 month ago - GlobeNewsWire

NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today anno...

2 months ago - GlobeNewsWire

NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

2 months ago - GlobeNewsWire

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

3 months ago - GlobeNewsWire

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

3 months ago - GlobeNewsWire

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

3 months ago - GlobeNewsWire

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

3 months ago - GlobeNewsWire

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

4 months ago - GlobeNewsWire

PAVmed's (PAVM) CEO Lishan Aklog on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Conference call to be held today at 4:30 p.m. Eastern time

5 months ago - GlobeNewsWire

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...

5 months ago - GlobeNewsWire

The company has multiple promising medical devices in various states of regulatory approval, although three of these have already entered the commercial stage. Yet, like for most pre-revenue medical dev...

5 months ago - Seeking Alpha

NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today annou...

7 months ago - GlobeNewsWire

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2020 Results and Business Update - Earnings Call Transcript

7 months ago - Seeking Alpha

Conference call to be held today at 4:30 p.m. Eastern time

7 months ago - GlobeNewsWire

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announ...

8 months ago - GlobeNewsWire

NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announ...

8 months ago - GlobeNewsWire

NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announ...

9 months ago - GlobeNewsWire

NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company is ...

10 months ago - GlobeNewsWire

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that medical di...

10 months ago - GlobeNewsWire

NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majori...

10 months ago - GlobeNewsWire

Executed LOI with Canon Virginia, Inc. to develop and implement commercial grade processes to manufacture molded resorbable pediatric ear tubes from aqueous silk fibroin

10 months ago - GlobeNewsWire

PAVMed Is About To Enter The Commercialization Phase

10 months ago - Seeking Alpha

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2020 Results and Business Update - Earnings Call Transcript

10 months ago - Seeking Alpha

Conference call to be held today at 4:30 p.m. Eastern time

10 months ago - GlobeNewsWire

PAVmed: Small Medical Device Maker With New FDA Approval And Multiple Catalysts

11 months ago - Seeking Alpha

NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has receive...

11 months ago - GlobeNewsWire

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Conference call to be held today at 4:30 p.m. Eastern time

1 year ago - GlobeNewsWire

NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the EsoCh...

1 year ago - GlobeNewsWire

NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has receive...

1 year ago - GlobeNewsWire

Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints

1 year ago - GlobeNewsWire

Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and f...

1 year ago - GlobeNewsWire

Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal cancer develops

1 year ago - GlobeNewsWire

Disposable single-use device designed to provide safer, more efficient and cost-effective ablation of dysplastic Barrett’s Esophagus, complementing Lucid Diagnostics’ EsoGuard™ and EsoCheck™ products

1 year ago - GlobeNewsWire

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Compan...

1 year ago - GlobeNewsWire

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received...

1 year ago - GlobeNewsWire

First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer

1 year ago - GlobeNewsWire

NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its...

1 year ago - GlobeNewsWire

PAVmed Has Multiple Paths To Growth

1 year ago - Seeking Alpha

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Conference call to be held on November 21, 2019 at 4:30 p.m. Eastern time

1 year ago - GlobeNewsWire

About PAVM

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusi... [Read more...]

Industry
Medical Devices
IPO Date
Apr 28, 2016
Stock Exchange
NASDAQ
Ticker Symbol
PAVM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PAVmed stock is "Strong Buy." The 12-month stock price forecast is 8.50, which is an increase of 72.76% from the latest price.

Price Target
$8.50
(72.76% upside)
Analyst Consensus: Strong Buy